57 results
424B5
SLNO
Soleno Therapeutics, Inc.
19 Jul 24
Prospectus supplement for primary offering
5:02pm
). With Breakthrough Therapy Designation, the FDA provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative … basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may
424B5
SLNO
Soleno Therapeutics, Inc.
6 May 24
Prospectus supplement for primary offering
4:58pm
provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may … supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other
424B5
SLNO
Soleno Therapeutics, Inc.
2 May 24
Prospectus supplement for primary offering
4:04pm
intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may also allow … basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may
8-K
EX-99.1
SLNO
Soleno Therapeutics, Inc.
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may
S-3ASR
zlbfg
2 Jan 24
Automatic shelf registration
4:06pm
8-K
EX-99.1
ekipl7o9vg86s1
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
z81861iq
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
x80aq9uc491
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
22p0yc3kovcy5aips
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
msms68ygufjfk
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
avpj1dn2 9fdomgrpo
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
cvh4mk
15 Apr 21
Other Events
12:00am
8-K
EX-99.2
gyfbby43
15 Apr 21
Other Events
12:00am
8-K
EX-1.1
rv6f14pae
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
uspn3e0g
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
l98beo6mmg1s3s t55h
22 Oct 19
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
4dqckugsk49e4p9xug42
29 Apr 19
Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
4:03pm
424B3
fux5rv7 cke1xij2j
12 Apr 19
Prospectus supplement
4:41pm